Compare

Aprea Therapeutics, Inc. vs Cerenome, Inc. vs Cellectar Biosciences, Inc. vs Lipocine Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearAprea Therapeutics, Inc.
APRE
Cerenome, Inc.
CNSY
Cellectar Biosciences, Inc.
CLRB
Lipocine Inc.
LPCN
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenuen/a$5.21Mn/a$1.98M
Revenue growth (YoY)n/a-10.5%n/a-82.3%
Gross marginn/an/an/an/a
Operating marginn/a-293.5%n/a-524.7%
Net marginn/a-429.4%n/a-487.1%
Net income-$12.60M-$22.39M-$21.79M-$9.63M
EPS (Diluted)-$1.93-$0.29-$8.35-$1.69
Operating cash flow-$12.89M-$20.77M-$23.12M-$9.76M
Free cash flown/a-$20.84M-$23.12Mn/a
Cash & equivalents$14.60M$4.26M$13.20M$5.21M
Total assets$15.93M$16.32M$14.98M$17.01M
Total liabilitiesn/a$12.33M$5.06M$2.53M
Shareholders' equity$12.44M$4.00M$8.54M$14.48M
Return on year-end equity-101.3%-560.2%-255.2%-66.5%
Shares outstanding8.19M138.68M4.24M6.16M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearAprea Therapeutics, Inc.Cerenome, Inc.Cellectar Biosciences, Inc.Lipocine Inc.
Latestn/a$5.21M
Ended 2025-12-31
n/a$1.98M
Ended 2025-12-31
1 year earliern/a$5.82M
Ended 2024-12-31
n/a$11.20M
Ended 2024-12-31
2 years earliern/a$4.91M
Ended 2023-12-31
n/a-$2.85M
Ended 2023-12-31
3 years earliern/an/an/a$500.0K
Ended 2022-12-31
4 years earliern/an/an/a$16.14M
Ended 2021-12-31